Hemodialysis patients who do not feel well at the end of a session are subject to an unidentified decrease in Cardiac Index. End-stage renal disease (ESRD) patients are at increased risk of complications and death from cardiovascular disease (CVD). In fact, mortality rates from CVD are up to 30 times higher for ESRD patients than those in the general population.
Though it’s extensively documented in literature, AV access flow is a commonly
Changes in blood pressure cannot quantify the cardiac status of hemodialysis patients. To get the most accurate assessment of cardiac function, the patient should be assessed with ultrasound dilution technology.
Hemodynamic monitoring helps you gain insight into the hemodynamic profile of an individual HD patient with regard to cardiac performance, congestion and compensation of Access Flow (indicated by AF/CO). It also allows you to identify patients at increased risk for mortality, can improve hemodialysis treatment and patient prognosis and cuts down on external resources and referrals.
The updated cardiac function parameters for the Flow-QC® are: